Paul Gilwit, MD
Ophthalmology · Ft Lauderdale, FLNPI 1164486585
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $269 of the $440 with a category attached, or 61.1%. Mallinckrodt Hospital Products Inc. accounts for 69.4% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $155 and has fallen 78.7% since, to $33 in 2025. That places this record below the midpoint for ophthalmology clinicians in FL, where the typical reported total is $1,824.
Across 17 payments — averaging $25.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$306
- Dompe US, Inc.$90
- Eyevance Pharmaceuticals LLC$23
- Akorn, Inc.$22
What the payments were for
- Food & beverage$26961%
- Education$17139%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 12 | $306 |
| Dompe US, Inc. | 3 | $90 |
| Eyevance Pharmaceuticals LLC | 1 | $23 |
| Akorn, Inc. | 1 | $22 |
How this compares
$440 in reported general payments places this provider in the 20th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 34 | $29,171 |
| CombiganBrimonidine Tartrate/Timolol | 21 | $6,936 |
| Travoprost | 17 | $1,747 |
| Prednisolone Acetate | 28 | $1,252 |
| Ketorolac Tromethamine | 68 | $1,120 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 31 | $1,054 |
| Latanoprost | 100 | $1,005 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 62 | $676 |
| Dorzolamide Hcl | 26 | $479 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 27 | $355 |
| Ofloxacin | 17 | $195 |
| Timolol Maleate | 16 | $181 |
| Acetazolamide ErAcetazolamide | 14 | $37 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Ft Lauderdale
- Robert KrammFt Lauderdale$114K
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- Robert WeinstockLargo$605K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.